Amasheya ephayona lokugomela i-corona i-BioNTech akhuphuka kabusha ngemuva kokwehla kwamanani ezinsukwini zakamuva zokuhweba.
Ngemuva kokuwa ngaphezu kwekota muva nje ngenxa yokuncishiswa kokuthengiswa yimbangi uModerna kanye nethemba lokuthola iphilisi le-corona elisebenzayo kwa-Pfizer ekuhwebeni okukhulu kwaseNew York, amasheya e-BioNTech ahwebe ngo-11,98% e-US ku-NASDAQ ngoMsombuluko. lilinganiselwa ku-242,60 US dollar. Inkampani ese-Mainz izoshicilela izibalo zayo zekota kulezi zinsuku.
Ochwepheshe babheka ukuhlehla kwakamuva njengehaba. "Ngisho noma ukugoma kabusha isitokwe semithi yokugoma akusasetshenziswa njengamanje: akukho ukwethuka okudayiswayo," kusho umbhali wezincwadi zesitoko uHans Bernecker ngoMsombuluko. Kuze kube manje, imishanguzo emisha yokunciphisa inkambo yesifo ayikashintshi iqiniso lokuthi isidingo sokugoma sisakhuthazwa. U-Olga Smolentseva, umhlaziyi wakwaBryan Garnier, osola ukuthi ukugoma ngeke kuphazamiseke, ubona ngendlela efanayo. Ngokusho kochwepheshe, okwamanje, ukugoma kuseyindlela ephumelela kakhulu yokuqukatha ukusabalala kwegciwane.
I-BioNTech ngemuva kokwehla kwezintengo: amasheya endaweni enhle ekuqaleni kwesonto
Amasheya e-BioNTech akwazile ukusimama kancane ngoMsombuluko ekuseni ngemuva kokuwa kakhulu ngesonto eledlule. Isabelo esisesiteji sokuhweba se-Tradegate senyuke ngamaphesenti angu-5,6 saya kuma-euro angu-201,30.
NgoLwesihlanu, izindaba zokuthi i-Pfizer inephilisi le-coronavirus elisebenzayo zibeka ingcindezi enkulu ezintweni zokugoma. Iphilisi lenkampani eyenza imithi kuthiwa linciphisa ingozi yokulaliswa esibhedlela noma yokufa ngamaphesenti angu-89. Ukugunyaza kufanele kuthunyelwe manje.
Abatshalizimali besaba ukuthi imigomo ye-coronavirus manje ingase ibe nesidingo esincane kakhulu. Imithi yokugoma kungenzeka ihlale iyingxenye ebaluleke kakhulu emikhankasweni ye-corona kazwelonke. Ikakhulukazi, ama-revaccinations angadlala indima ebalulekile.
Kusukela cishe enyangeni yesikhombisa, yesishiyagalombili noma yesishiyagalolunye, amazinga e-antibody ayehla ngemva kokugonywa ngomgomo we-BioNTech/Pfizer. Bese kuba khona ukutheleleka nge-coronavirus. "Siyabona futhi ukuthi uma uthelelekile, lesi sifo siqhubekela phambili kubantu abagonyiwe, imvamisa kancane, futhi ukukhula okunamandla kuyivelakancane," kusho umphathi we-BioNTech u-Ugur Sahin. “Futhi sinemininingwane yocwaningo ekhombisa ukuthi imigomo ye-booster ibuyisela ukuvikeleka emigomeni. Lokhu kusebenza futhi kunketho ye-Delta.
Namuhla, lapho i-BioNTech yethula idatha yekota yesithathu, kungase kube nethuba lokuthuthuka kwebhizinisi okwengeziwe. Kodwa-ke, ngokuhamba kwesikhathi, kugxilwe ekuthuthukisweni okuqhubekayo - ikakhulukazi, amaphrojekthi we-oncology. Uma sikhuluma ngobuchwepheshe, isitokwe se-BioNTech sisanda kwazi ukuvikela ulayini wezinsuku ezingama-200. Iyaqhubeka nokusebenza njengokwesekwa okubalulekile. Umnikazi wamasheya uhlala eqiniseka ngokusobala esikhathini eside.
